News Detail
New Delhi, 22 June 2024: Sun Pharmaceutical Industries on Friday said it has inked a licensing pact with Takeda Pharmaceutical Company to commercialise a novel gastrointestinal drug in India.
The company has entered into a non-exclusive patent licensing agreement with ......
View Details
Source : Business Standard
Takeda Pharmaceutical Company
Sun Pharma
Pharmaceutical industry
Healthcare in India
Generic Pharmaceuticals
Pharmaceuticals (NEC)
acid peptic disorders
FDA
Major
GERD
Sun Pharmaceutical Industries
Erosive esophagitis
CEO
Vonoprazan
leader
healthcare practitioners
Mumbai
infection
Gastroesophageal Reflux Disease
India
clarithromycin
Kirti Ganorkar
amoxicillin
reflux esophagitis
Related News
- Cipla gets nod to market Afrezza insulin inhalation powder in India (12-12-2024)
- UK regulator probes anti-depressants safety alerts after suicide link (12-12-2024)
- Haryana Food Department to Crack Down on Fake Protein Supplements After Major Bust (12-12-2024)
- Drug inspector sentenced to 3-yr rigorous imprisonment (12-12-2024)
- 11.12 crore worth of short-shelf life medicines expired due to delayed supply to TNMSC: CAG Report (12-12-2024)
- Ayush Ministry amends D&C Act to add Homoeopathy, Sowa Rigpa books and Pharmacopoeias (12-12-2024)
- Construction of all three bulk drug parks are in progress: Ministry of chemicals (12-12-2024)
- Four-member gang nabbed for selling ‘Mephentermine Sulphate’ injections in Hyderabad (12-12-2024)
- Combining BCL-2 and BTK inhibitors shows promise in chronic lymphocytic leukemia (CLL) (11-12-2024)
- Punjab cop arrests man for narcotic drugs case, gets fined by court (11-12-2024)